Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.
about
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerEGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinibRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCUnderstanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung CancerThe latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agentsMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularRole of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatmentsManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerIrreversible EGFR-TKIs: dreaming perfectionTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesMolecular pathology of lung cancer: key to personalized medicine.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patientsAcquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsAfatinib for the treatment of metastatic non-small cell lung cancerPharmGKB summary: very important pharmacogene information for the epidermal growth factor receptorMechanisms of action of therapeutic antibodies for cancerEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesPredictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.Molecular Testing of Lung CancersOsimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapyGlucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidenceEfficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutationsEGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinomaMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularPerformance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort studyToward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer.Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.Unique molecular landscapes in cancer: implications for individualized, curated drug combinations.Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.Advances in fine needle aspiration cytology for the diagnosis of pulmonary carcinoma.
P2860
Q24604601-5D9F0EFC-0B59-4989-A326-ADE2D8344D15Q24606177-A36AA516-EFE7-4AD5-9E68-8BBA1C78C1BEQ26747276-17FFD50E-16DA-48FA-9537-84EEC6842EE3Q26748581-703733C5-E78E-4D99-84E0-5A4D9937BE3FQ26764917-36AC2C87-4C08-4ADE-9708-63016A017668Q26823305-EF956A1A-7B00-4600-881B-447755615F29Q26823903-A026FE8F-19DE-444A-95D4-45206C089FB9Q26828860-FEBF603C-C1BC-43B6-8344-3F2382CE5ECCQ26852206-9D6CB568-F7A7-4AD0-9611-3388EB200FC2Q26865779-0A4303E8-35E9-4CAF-94C3-2BA805DFD626Q26866186-8AC6C064-7DC2-4D1F-9630-6D6FE06E92ECQ27014117-7FE928F5-FFA0-4F00-A182-8981F6DCEF01Q27691299-F128A460-BDA7-47E6-9045-9D206E08CB21Q27852116-EE409021-AE05-4FC9-826F-B2A12A8100B4Q27852993-1D9621C6-78E0-47F9-8AC4-A18CCC9FF1FBQ27853162-6A1DD298-8B90-4353-9248-CF4CB624BD66Q28075291-D91D772A-6FE3-4A30-BE06-1D9EA22853F0Q28082181-BB01275E-47AA-40BC-AB28-B8F30D937F3EQ28382921-DF5C5A1F-3F15-4616-B7A9-DBC7E7BF3943Q28385366-90BF8A17-41FA-48C7-92A7-15DC1C609E58Q28394310-74D71569-6C7C-45FF-B477-AC4A2D7FA216Q33567383-EB8109FB-903B-4861-81C7-F0A1A723EFB7Q33729715-03E7FF14-217E-403C-8B78-3ED0BE5BCDDBQ33757134-6C8393E9-60A0-447B-AEBA-0172A90A8BC2Q33873274-9AB4A3B2-4DFA-49BF-BA4F-B4AFB6994A44Q33938441-527D5702-8BD3-4213-8F3F-BC96311A11B6Q34011705-10B0193D-5995-4430-B3C2-8CC9C954B366Q34055400-077B11F7-88C8-42DA-9330-F878A4639AF6Q34108365-67414341-DD96-43F1-A7A6-4F137C670359Q34159011-64147072-7D83-4617-8039-3641D8309C82Q34235130-9917D6F3-4925-4D53-951E-5CD6DEFA0FD2Q34260686-C473408A-4207-49AF-87DD-F36A614233FFQ34404209-654C056C-0148-4EFD-8A4C-AEF6E0335923Q34497467-0D7DFD4A-48A5-4C4B-A6B9-E7AC13940650Q34550460-211E4146-E03D-4140-811A-A57DD75F46DBQ34608584-1436EE27-04F0-4EF2-9CE3-C38775E1301DQ34694358-7432A20C-9E6A-4472-A06F-A482314A8B5DQ34938532-3FE5B298-2EA2-4E87-AF59-FC9B6EBC3FA2Q35076221-9AFA48D6-D4F9-47E8-A834-C5957215CE9FQ35110001-A205B378-52F3-47B5-A6DD-CBAD1C39398E
P2860
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Rebiopsy of lung cancer patien ...... cked nucleic acid-based assay.
@ast
Rebiopsy of lung cancer patien ...... cked nucleic acid-based assay.
@en
Rebiopsy of lung cancer patien ...... cked nucleic acid-based assay.
@nl
type
label
Rebiopsy of lung cancer patien ...... cked nucleic acid-based assay.
@ast
Rebiopsy of lung cancer patien ...... cked nucleic acid-based assay.
@en
Rebiopsy of lung cancer patien ...... cked nucleic acid-based assay.
@nl
prefLabel
Rebiopsy of lung cancer patien ...... cked nucleic acid-based assay.
@ast
Rebiopsy of lung cancer patien ...... cked nucleic acid-based assay.
@en
Rebiopsy of lung cancer patien ...... cked nucleic acid-based assay.
@nl
P2093
P2860
P50
P1476
Rebiopsy of lung cancer patien ...... cked nucleic acid-based assay.
@en
P2093
Geoffrey R Oxnard
Gregory J Riely
Khedoudja Nafa
Maria E Arcila
Maureen F Zakowski
Stephen B Solomon
Vincent A Miller
P2860
P304
P356
10.1158/1078-0432.CCR-10-2277
P407
P577
2011-01-19T00:00:00Z